IHS Chemical Week

Regions :: Western Europe :: Switzerland

Lonza and Sorrento Therapeutics sign research license agreement

12:02 AM MDT | August 7, 2013 | Deepti Ramesh

Lonza and Sorrento Therapeutics (San Diego), a publicly traded, development-stage biopharmaceutical company, say that they have signed a nonexclusive research license agreement for access to Lonza’s GS Xceed Gene Expression System.  The GS Xceed System will be used in the generation of stable expression cell lines for the production and development of therapeutic antibodies in Sorrento’s product portfolio. The research license agreement will give Sorrento access to Lonza’s GS technology for use in Sorrento’s maturing pipeline of...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa